t6平台娱乐客户端

    <sub id="xftxb"><dfn id="xftxb"><mark id="xftxb"></mark></dfn></sub>

        <address id="xftxb"></address>

        <sub id="xftxb"><listing id="xftxb"></listing></sub>
        <address id="xftxb"><dfn id="xftxb"><mark id="xftxb"></mark></dfn></address><address id="xftxb"></address>
        <sub id="xftxb"><var id="xftxb"><output id="xftxb"></output></var></sub>

        <sub id="xftxb"><dfn id="xftxb"><mark id="xftxb"></mark></dfn></sub>
        <address id="xftxb"><listing id="xftxb"></listing></address>

          <sub id="xftxb"><dfn id="xftxb"><mark id="xftxb"></mark></dfn></sub>
          <sub id="xftxb"><dfn id="xftxb"></dfn></sub>
          <address id="xftxb"><listing id="xftxb"></listing></address><sub id="xftxb"><var id="xftxb"><mark id="xftxb"></mark></var></sub>
          <thead id="xftxb"><delect id="xftxb"><output id="xftxb"></output></delect></thead>

          <sub id="xftxb"><dfn id="xftxb"><mark id="xftxb"></mark></dfn></sub>
            <address id="xftxb"></address>

          <address id="xftxb"><dfn id="xftxb"></dfn></address>

          <address id="xftxb"></address>

            <sub id="xftxb"><dfn id="xftxb"></dfn></sub><address id="xftxb"><listing id="xftxb"></listing></address>

            Guangming Online> Editor’s Pick

            Antiviral drug Remdesivir to be applied in clinical trials Thursday

            CHINA-HUBEI-WUHAN-ANTIVIRAL DRUG-REMDESIVIR-CONFERENCE (CN)

            Wang Chen (1st R), vice president of the Chinese Academy of Engineering and president of the Chinese Academy of Medical Sciences (CAMS), speaks at a conference in Wuhan, central China's Hubei Province, Feb. 5, 2020. The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) are expected to start taking the drug on Thursday, according to an official conference Wednesday. (Xinhua/Cheng Min)

            BEIJING, Feb. 5 (Xinhua) -- The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) are expected to start taking the drug on Thursday, according to an official conference Wednesday.

            The approval is jointly supported by the Ministry of Science and Technology (MOST), the National Health Commission and the National Medical Products Administration.

            Remdesivir is a drug developed by Gilead Sciences, an American pharmaceutical company, said Cao Bin, head of the drug's clinical trial program, at the conference held by the MOST at the Wuhan Jinyintan Hospital, central China's Hubei Province.

            The drug has shown good antiviral activity against SARS and MERS coronavirus in previous cell and animal experiments. Its clinical trials against Ebola infections have been conducted abroad. In related domestic research, it has also shown fairly good antiviral activity against the 2019-nCoV at the cellular level, said Cao.

            A total of 761 patients have been enrolled in the trials, which will adopt a randomized, double-blind and placebo-controlled study method.

            The trials, led by the China-Japan Friendship Hospital and the Institute of Materia Medica under the Chinese Academy of Medical Sciences (CAMS), will be conducted in several hospitals in Wuhan, including the Wuhan Jinyintan Hospital.

            Hopes have been pinned on the drug, but we have to wait for results of its actual effectiveness in the clinical trials, said Wang Chen, vice president of the Chinese Academy of Engineering and president of the CAMS.

            [ Editor: SRQ ]

              <sub id="xftxb"><dfn id="xftxb"><mark id="xftxb"></mark></dfn></sub>

                  <address id="xftxb"></address>

                  <sub id="xftxb"><listing id="xftxb"></listing></sub>
                  <address id="xftxb"><dfn id="xftxb"><mark id="xftxb"></mark></dfn></address><address id="xftxb"></address>
                  <sub id="xftxb"><var id="xftxb"><output id="xftxb"></output></var></sub>

                  <sub id="xftxb"><dfn id="xftxb"><mark id="xftxb"></mark></dfn></sub>
                  <address id="xftxb"><listing id="xftxb"></listing></address>

                    <sub id="xftxb"><dfn id="xftxb"><mark id="xftxb"></mark></dfn></sub>
                    <sub id="xftxb"><dfn id="xftxb"></dfn></sub>
                    <address id="xftxb"><listing id="xftxb"></listing></address><sub id="xftxb"><var id="xftxb"><mark id="xftxb"></mark></var></sub>
                    <thead id="xftxb"><delect id="xftxb"><output id="xftxb"></output></delect></thead>

                    <sub id="xftxb"><dfn id="xftxb"><mark id="xftxb"></mark></dfn></sub>
                      <address id="xftxb"></address>

                    <address id="xftxb"><dfn id="xftxb"></dfn></address>

                    <address id="xftxb"></address>

                      <sub id="xftxb"><dfn id="xftxb"></dfn></sub><address id="xftxb"><listing id="xftxb"></listing></address>

                      足球比分

                      ub8平台注册

                      体足即时比分

                      www.亚搏

                      盛皇彩票

                      足球推单|平台

                      m体育

                      幸运彩票官网注册首页

                      365体育平台

                       

                      足球比分

                      ub8平台注册

                      体足即时比分

                      www.亚搏

                      盛皇彩票

                      足球推单|平台

                      m体育

                      幸运彩票官网注册首页

                      365体育平台